Prostate Cancer Cell Line (CWR-R1-I567)
Human prostate cancer cell line, CWR-R1-I567 is the cell clone of CWR-R1 (EMN024-FP) that is engineered using TAL effector nuclease so that the cell harbors Androgen receptor genome intron 4-7 inversion and results in the expression of ARv567es only.
Highlights:
- Expresses ARv567es
Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. The androgen receptor (AR) helps prostate cancer cells to survive and is a target for many anti cancer research studies by looking at inhibition.
From the laboratory of Scott M. Dehm, PhD, University of Minnesota, Twin Cities.
Human prostate cancer cell line, CWR-R1-I567 is the cell clone of CWR-R1 (EMN024-FP) that is engineered using TAL effector nuclease so that the cell harbors Androgen receptor genome intron 4-7 inversion and results in the expression of ARv567es only.
Highlights:
- Expresses ARv567es
Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. The androgen receptor (AR) helps prostate cancer cells to survive and is a target for many anti cancer research studies by looking at inhibition.
From the laboratory of Scott M. Dehm, PhD, University of Minnesota, Twin Cities.
This product is for sale to Nonprofit customers only. For profit customers, please Contact Us for more information.
| Product Type: | Cell Line |
| Name: | CWR-R1-I567 |
| Cell Type: | Prostate Cancer |
| Morphology: | Epithelial cells |
| Organism: | Human |
| Source: | Prostate |
| Biosafety Level: | BSL 2 |
| Growth Conditions: | RPMI Medium 1640 - L-Glutamine (Invitrogen 11875), 10% FBS, 1xPen/Strep |
| Subculturing: | Seed CWR-R1-AD1 cell at 15X106/T75 flask, change medium twice a week and split 1 to 3 splitting once a week |
| Cryopreservation: | RPMI1640 , 20 % FBS and 10 %DMSO |
| Comments: | Give 48 hours for the cell to settle after thawing |
| Storage: | Liquid nitrogen |
| Shipped: | Dry Ice |
- Nyquist MD, Li Y, Hwang TH, et al. TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad Sci U S A. 2013;110(43):1749217497. doi:10.1073/pnas.1308587110.
- Chan SC, Selth LA, Li Y, et al. Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015;43(12):58805897. doi:10.1093/nar/gkv262.
- Dalal K, Che M, Que NS, et al. Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions. Mol Cancer Ther. 2017;16(10):22812291. doi:10.1158/1535-7163.MCT-17-0259.
- Yin Y1, Li R2, Xu K, Ding S2, Li J2, Baek G, Ramanand SG5, Ding S, Liu Z2,, Gao Y, Kanchwala MS6, Li X, Hutchinson R, Liu X, Woldu SL, Xing C6, Desai NB, Feng FY, Burma S, de Bono JS, Dehm SM, Mani RS, Chen BPC, Raj GV. Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation. Cancer Res. 2017 Sep 15;77(18):4745-4754. doi: 10.1158/0008-5472.CAN-17-0164. Epub 2017 Jul 28.
If you publish research with this product, please let us know so we can cite your paper.
